1. Is the Glasgow Prognostic Score Applicable to Both Early- and Advanced-Stage Gastric Cancers?
- Author
-
Shinobu Tsuchida, Tetsuo Maeda, Tomoyuki Wakahara, Kiyonori Kanemitsu, Nozomi Ueno, Akihiro Toyokawa, and Takuro Yoshikawa
- Subjects
medicine.medical_specialty ,Multivariate analysis ,Survival ,medicine.medical_treatment ,Gastroenterology ,Prognostic score ,03 medical and health sciences ,0302 clinical medicine ,Carcinoembryonic antigen ,Internal medicine ,medicine ,Hypoalbuminemia ,biology ,business.industry ,Advanced stage ,Cancer ,medicine.disease ,030220 oncology & carcinogenesis ,biology.protein ,030211 gastroenterology & hepatology ,Gastrectomy ,Original Article ,business ,Gastric cancer ,Carbohydrate antigen - Abstract
Background The Glasgow prognostic score (GPS) has been reported as a sensitive prognostic marker for gastric cancer. This study aimed to investigate whether the GPS is equally applicable to patients with early-stage and advanced-stage gastric cancers. Methods Patients (n = 544) who underwent elective gastrectomy for gastric cancer between 2007 and 2015 were retrospectively studied. GPSs of 2, 1, and 0 were allocated to patients with both an elevated C-reactive protein level (> 1.0 mg/dL) and hypoalbuminemia (< 3.5 mg/dL), patients with only one of these abnormalities, and patients with neither abnormality, respectively. The prognostic factors relevant to patients with early-stage (pStage I, n = 304) and advanced-stage (pStage II, III, and IV, n = 240) gastric cancer were analyzed through univariate and multivariate analyses. Results In the early-stage group, only the serum carbohydrate antigen (CA) 19-9 level (P = 0.037) was a significant prognostic factor in the multivariate analysis; the GPS was not significant (P = 0.095). In the advanced-stage group, an American Society of Anesthesiologists physical status of 3 or 4 (P = 0.032), elevated carcinoembryonic antigen (CEA) (P = 0.043) and CA19-9 (P = 0.045) levels, a GPS 1 - 2 (P = 0.017), and type 4 tumor (P = 0.020) correlated significantly with worse overall survival. Conclusions GPS is a simple and useful prognostic score for patients with advanced-stage, but is not applicable to early-stage patients.
- Published
- 2018